NVISION Eye Centers Partners with Parkhurst NuVision to Expand Clinical Trials in Ophthalmology

NVISION Eye Centers, a prominent provider of eye care services nationwide, announced a strategic collaboration with Parkhurst NuVision of San Antonio, Texas, through its subsidiary NVision Clinical Research, LLC.

This partnership aims to advance clinical trials in ophthalmology drug development, leveraging Parkhurst NuVision's expertise in vision correction solutions and extensive experience in conducting ophthalmologic clinical trials.

Parkhurst NuVision, led by Dr. Gregory Parkhurst, MD, renowned as one of the "Top 40 Under 40" Most Influential Ophthalmologists globally by The Ophthalmologist, specializes in a wide array of procedures including LASIK and EVO ICL. The practice has earned recognition for excellence in Presbyopia, Refractive Surgery, Dry Eye, Cataract, Glaucoma, and Keratoconus trials, bolstered by recent accolades and a favorable FDA inspection report.

"We are thrilled to have Dr. Parkhurst join our family of dedicated professionals who exemplify our Patient First ethos," remarked Chris Karkenny, CEO of NVISION. "PNV’s active clinical trial practice increases our access to patients interested in trial participation, quicker study start-up for our trial partners, and a powerful dimension to our clinical care commitment to our patients."

Dr. Parkhurst expressed enthusiasm about the collaboration, highlighting Parkhurst NuVision’s reputation as a thought leader in ophthalmology research. "Our team has become known as a thought leader in ophthalmology with a reputation for performing high-quality research," he noted. "We have been one of the top-enrolling sites in nearly every one of the dozens of FDA-monitored clinical studies we have participated in over the past 10+ years."

The collaboration between NVISION and Parkhurst NuVision is expected to enhance access to cutting-edge treatments for patients within their respective communities. "We are delighted to partner with NVISION to expand access to cutting-edge treatments for our patient base and the large network of referring doctors in our community," Dr. Parkhurst added.

This partnership signifies a significant step forward in advancing ophthalmic research and underscores both organizations’ commitment to innovation and patient care in the field of eye health.